DR. GARY R PASTERNACK, M.D., PH.D.
Medical Practice at Camden St, Baltimore, MD

6713654, Mar 30, 2004

Aug 28, 2000

09/486550

Craig A. Townsend - Baltimore MD
James D. Dick - Upperco MD
Gary R. Pasternack - Baltimore MD
Francis P. Kuhajda - Lutherville MD
Nicole M. Parrish - Ellicott City MD

The Johns Hopkins University School of Medicine - Baltimore MD

C07C31500

568 27, 568 28, 568 31

This invention provides methods for treating a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SO —Z—CO—Y, where R is an alkyl group having 6-20 carbons; Z is a radical selected from —CH —, —O—, and —NH—, two of these radicals coupled together, or —CH CH —; Y is —NH , O—CH —C H , —CO—CO—O—CH , or O—CH ; and n is 1 or 2. It has been discovered that these compounds inhibit growth of microbial cells which synthesize -substitued, -hydroxy fatty acids, particularly corynemycolic acid, nocardic acid, and mycolic acid. These compounds may be used to inhibit growth of mycobacterial cells, such as drug-resistant and.

6040173, Mar 21, 2000

Jun 6, 1995

8/466743

Gary R. Pasternack - Baltimore MD

Johns Hopkins University - Baltimore MD

C12N 1500, C07H 2104

4353201

Three mammalian proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.

6930175, Aug 16, 2005

Jun 12, 2000

09/591500

Gary R. Pasternack - Baltimore MD, US
Jonathan R. Brody - Potomac MD, US
Shrihari S. Kadkol - Ellicott City MD, US

The Johns Hopkins University School of Medicine - Baltimore MD

C07K016/18

5303881, 5303871

pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade≧5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation.

5981575, Nov 9, 1999

Jan 27, 1998

9/000157

Francis P. Kuhajda - Lutherville MD
Gary R. Pasternack - Baltimore MD
Craig A. Townsend - Baltimore MD
Neelakandha S. Mani - Baltimore MD

Johns Hopkins University, The - Baltimore MD

A01K 3104

514473

Weight loss was noted in nude mice treated with cerulenin, a non-competitive inhibitor of FAS. Sustained reduction of adipocyte mass in humans without toxicity would significantly impact disease prevention worldwide. Aside from psychological and self-esteem improvement, weight loss via reduction of adipocyte mass may: (1) ameliorate hyperglycemia associated with non-insulin-dependent diabetes mellitus thereby reducing diabetic complications such as arterial disease, blindness, cataracts, etc. , (2) reduce hypertension, (3) reduce risk of coronary artery vascular disease and stroke, and (4) reduce the risk of other complications of massive obesity such as osteoarthritis, surgical complications, etc. There is also potential use in livestock and poultry to reduce the saturated fat content of meat products. Therefore FAS inhibitors are disclosed herein as novel agents for weight reduction.

5734022, Mar 31, 1998

Sep 28, 1994

8/314503

Gary R. Pasternack - Baltimore MD

The Johns Hopkins University - Baltimore MD

C07K 1618, C07K 1630, C07K 1644

5303871

Three mammalian nuclear proteins are disclosed which are useful in the diagnosis and prognosis of tumors of lymphoid and epithelial origin. The three proteins are immunologically related to each other. The level of expression of the proteins correlates with the malignant potential of lymphoid and epithelial tumors. In addition, in some cases the subcellular location of the proteins is indicative of malignant potential. Antibodies reactive with the proteins are disclosed as diagnostic tools, as are nucleic acid probes and primers for quantitating the messenger RNAs encoding the proteins. Methods for preparing and purifying the proteins are also taught.

5759837, Jun 2, 1998

Jan 24, 1994

8/188425

Francis P. Kuhajda - Lutherville MD
Gary R. Pasternack - Baltimore MD

John Hopkins University - Baltimore MD

C12N 904, C12N 910

435193

Fatty acid synthase (FAS) is overexpressed in carcinomas with poor prognosis, but little FAS expression is identified in normal tissues Inhibition of fatty acid synthesis is selectively toxic to carcinoma cells, while normal cells with low FAS activity are resistant. This invention provides a method of treating cancer patients where fatty acid synthesis by cells of the patient's tumor is inhibited with resultant interruption of the disease process.

2008019, Aug 14, 2008

Jun 18, 2007

11/764587

Gary Pasternack - Baltimore MD, US
Alexander Sulakvelidze - Towson MD, US

Intralytix, Inc. - Baltimore MD

C12N 7/00

4352351

The present invention is directed to isolated bacteriophage, and methods of using bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by . The present invention also contemplates the use of bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Listeria monocytogenes.

2005024, Nov 3, 2005

Jul 1, 2005

11/173082

Alexander Sulakvelidze - Baltimore MD, US
J. Morris - Baltimore MD, US
Zemphira Alavidze - Tbilisi, GE
Gary Pasternack - Baltimore MD, US
Torrey Brown - Severna Park MD, US

A61K045/00

424093600

Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.

5665874, Sep 9, 1997

Jun 5, 1995

8/469005

Francis P. Kuhajda - Lutherville MD
Gary R. Pasternack - Baltimore MD

John Hopkins University - Baltimore MD

C07H 2102, C07H 2104, C12P 1934, C12Q 168

536 243

A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.

2008029, Dec 4, 2008

May 31, 2007

11/806353

Alexander Sulakvelidze - Towson MD, US
Gary Pasternack - Baltimore MD, US

Intralytix, Inc. - Baltimore MD

C12N 7/00, C07H 21/04

4352351, 536 2372

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of O157:H7 in various settings.